Andrea Padoan1,2, Chiara Cosma2, Francesco Bonfante3, Foscarina Della Rocca4, Francesco Barbaro5, Claudia Santarossa4, Luigi Dall'Olmo6,7, Matteo Pagliari3, Alessio Bortolami3, Annamaria Cattelan5, Vito Cianci4, Daniela Basso1,2, Mario Plebani1,2. 1. Department of Medicine-DIMED, University of Padova, Padova, Italy. 2. Department of Laboratory Medicine, University-Hospital of Padova, Padova, Italy. 3. Laboratory of Experimental Animal Models, Division of Comparative Biomedical Sciences, Istituto Zooprofilattico Sperimentale delle Venezie, Legnaro, Italy. 4. Emergency Department, Padua University Hospital, Padova, Italy. 5. Infective and Tropical Disease Unit, Padua University Hospital, Padova, Italy. 6. Department of Surgical Oncological and Gastroenterological Sciences - DISCOG, University of Padova, Padova, Italy. 7. Veneto Institute of Oncology, IOV-IRCCS, Padova, Italy.
Abstract
OBJECTIVES: mRNA vaccines, including Comirnaty (BNT162b2 mRNA, BioNTech-Pfizer), elicit high IgG and neutralizing antibody (NAb) responses after the second dose, but the progressive decrease in serum antibodies against SARS-CoV-2 following vaccination have raised questions concerning long-term immunity, decreased antibody levels being associated with breakthrough infections after vaccination, prompting the consideration of booster doses. METHODS: A total number of 189 Padua University-Hospital healthcare workers (HCW) who had received a second vaccine dose were asked to collect serum samples for determining Ab at 12 (t12) and 28 (t28) days, and 6 months (t6m) after their first Comirnaty/BNT162b2 inoculation. Ab titers were measured with plaque reduction neutralization test (PRNT), and three chemiluminescent immunoassays, targeting the receptor binding domain (RBD), the trimeric Spike protein (trimeric-S), and surrogate viral neutralization tests (sVNT). RESULTS: The median percentages (interquartile range) for decrease in antibodies values 6 months after the first dose were 86.8% (67.1-92.8%) for S-RBD IgG, 82% (58.6-89.3%) for trimeric-S, 70.4% (34.5-86.4%) for VNT-Nab, 75% (50-87.5%) for PRNT50 and 75% (50-93.7%) for PRNT90. At 6 months, neither PRNT titers nor VNT-Nab and S-RBD IgG bAb levels correlated with age (p=0.078) or gender (p=0.938), while they were correlated with previous infection (p<0.001). CONCLUSIONS: After 6 months, a method-independent reduction of around 90% in anti-SARS-CoV-2 antibodies was detected, while no significant differences were found between values of males and females aged between 24 and 65 years without compromised health status. Further efforts to improve analytical harmonization and standardization are needed.
OBJECTIVES: mRNA vaccines, including Comirnaty (BNT162b2 mRNA, BioNTech-Pfizer), elicit high IgG and neutralizing antibody (NAb) responses after the second dose, but the progressive decrease in serum antibodies against SARS-CoV-2 following vaccination have raised questions concerning long-term immunity, decreased antibody levels being associated with breakthrough infections after vaccination, prompting the consideration of booster doses. METHODS: A total number of 189 Padua University-Hospital healthcare workers (HCW) who had received a second vaccine dose were asked to collect serum samples for determining Ab at 12 (t12) and 28 (t28) days, and 6 months (t6m) after their first Comirnaty/BNT162b2 inoculation. Ab titers were measured with plaque reduction neutralization test (PRNT), and three chemiluminescent immunoassays, targeting the receptor binding domain (RBD), the trimeric Spike protein (trimeric-S), and surrogate viral neutralization tests (sVNT). RESULTS: The median percentages (interquartile range) for decrease in antibodies values 6 months after the first dose were 86.8% (67.1-92.8%) for S-RBD IgG, 82% (58.6-89.3%) for trimeric-S, 70.4% (34.5-86.4%) for VNT-Nab, 75% (50-87.5%) for PRNT50 and 75% (50-93.7%) for PRNT90. At 6 months, neither PRNT titers nor VNT-Nab and S-RBD IgG bAb levels correlated with age (p=0.078) or gender (p=0.938), while they were correlated with previous infection (p<0.001). CONCLUSIONS: After 6 months, a method-independent reduction of around 90% in anti-SARS-CoV-2 antibodies was detected, while no significant differences were found between values of males and females aged between 24 and 65 years without compromised health status. Further efforts to improve analytical harmonization and standardization are needed.
Authors: Giulia Collatuzzo; Giovanni Visci; Francesco S Violante; Stefano Porru; Gianluca Spiteri; Maria Grazia Lourdes Monaco; Francesca Larese Fillon; Corrado Negro; Christian Janke; Noemi Castelletti; Giuseppe De Palma; Emanuele Sansone; Dana Mates; Silvia Teodorescu; Eleonóra Fabiánová; Jana Bérešová; Luigi Vimercati; Silvio Tafuri; Mahsa Abedini; Giorgia Ditano; Shuffield S Asafo; Paolo Boffetta Journal: Front Immunol Date: 2022-09-29 Impact factor: 8.786
Authors: Daniel Filchtinski; Magnus Sundberg; Heike Berthold; Laura Steller; José Kayser; Sanja Holz; Mario Hinze; Oxana Braeutigam; Johannes Schulte-Pelkum; Raimund Fiedler Journal: J Immunol Methods Date: 2022-03-15 Impact factor: 2.287